A 92-year-old woman with normal systolic function had recently begun using the newly approved phosphodiesterase III inhibitor cilostazol when she was admitted with lower-extremity pain. Cilostazol is
ObjectiveAlthough the association between admission glucose (AG) and major adverse cardiac events (MACE) is well-documented, its relationship with 30-day MACE in patients presenting with cardiac chest
All values are expressed as percentage of total plasma fatty acids, except for total plasma fatty acids. P values are for the comparison of *major, †cardiac and ‡cerebrovascular events with participan
